TapewireFind a company

person · Reporting owner

ANG ROBERT

Disclosed activity across 2 companies

Tapewire entity
80065
SEC CIK
0001741283

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Neon Therapeutics, Inc.NTGN · Entity 149433Chief Business OfficerFebruary 27, 2019March 01, 2019
Vor Biopharma Inc.VOR · Entity 4763Director · PRESIDENT AND CEOMay 06, 2025May 07, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Neon Therapeutics, Inc.

Report date February 27, 2019 · Filed March 01, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect279,525 Reported balance After 2019-02-27 transaction · row 1
1 source row

Row 1 · 2019-02-27 · Grant · Acquired 20,000 · Balance 279,525

F1: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 · Expires 2029-02-26Direct40,000 Reported balance After 2019-02-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-02-27 · Grant · Acquired 40,000 · Balance 40,000

F2: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.

Vor Biopharma Inc.

Report date May 06, 2025 · Filed May 07, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect911,318 Reported balance After 2025-05-06 transaction · row 1
1 source row

Row 1 · 2025-05-06 · Tax withholding · Disposed 2,361 · Balance 911,318

F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 06, 2025 Filed May 7, 2025 20:05 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $0.56 $1,322.16
Disclosure

SEC source: 0001415889-25-012229 · form4-05072025_080553.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 911,318

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
May 01, 2025 Filed May 2, 2025 20:28 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,522 $0.66 $1,664.52
Disclosure

SEC source: 0001415889-25-011803 · form4-05022025_080547.xml · nonDerivative · entry 2

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 913,679

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
May 01, 2025 Filed May 2, 2025 20:28 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,751 $0.66 $1,815.66
Disclosure

SEC source: 0001415889-25-011803 · form4-05022025_080547.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 916,201

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
February 06, 2025 Filed Feb 7, 2025 21:36 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,787 $1.50 $4,180.50
Disclosure

SEC source: 0001415889-25-003366 · form4-02072025_090218.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 918,952

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 825,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 17

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 825,000

Underlying: Common Stock · 825,000 shares

Expires 2035-02-02

F12 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 470,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 16

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 470,000

Underlying: Common Stock · 470,000 shares

Expires 2034-01-28

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F11 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 470,000 $0.00 Strike: $2.41 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 15

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 470,000 shares

Expires 2034-01-28

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F11 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 257,500 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 14

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,500

Underlying: Common Stock · 257,500 shares

Expires 2033-02-05

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 257,500 $0.00 Strike: $5.55 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 13

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 257,500 shares

Expires 2033-02-05

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 172,500 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 12

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,500

Underlying: Common Stock · 172,500 shares

Expires 2032-08-31

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 172,500 $0.00 Strike: $4.97 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 11

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 172,500 shares

Expires 2032-08-31

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 376,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 10

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,000

Underlying: Common Stock · 376,000 shares

Expires 2032-01-31

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 376,000 $0.00 Strike: $8.63 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 9

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 376,000 shares

Expires 2032-01-31

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 51,060 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 8

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,060

Underlying: Common Stock · 51,060 shares

Expires 2031-02-04

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 19, 2021, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 51,060 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 7

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 51,060 shares

Expires 2031-02-04

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 19, 2021, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 652,086 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 6

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 652,086

Underlying: Common Stock · 652,086 shares

Expires 2030-08-20

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: Immediately exercisable.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 652,086 $0.00 Strike: $1.90 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 5

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 652,086 shares

Expires 2030-08-20

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: Immediately exercisable.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 147,294 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 4

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,294

Underlying: Common Stock · 147,294 shares

Expires 2030-03-09

F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date.

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: Immediately exercisable.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 147,294 $0.00 Strike: $2.18 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 3

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 147,294 shares

Expires 2030-03-09

F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · shares: On February 4, 2021, the Reporting Person filed a Form 3 which inadvertently reported that this stock option was for 147,293 shares, when in fact it was for 147,294 shares.

F5 · derivative.exercise_date: Immediately exercisable.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantCommon Stock 137,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · nonDerivative · entry 2

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 921,739

F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 03, 2025 Filed Feb 6, 2025 02:23 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 3,248 $1.34 $4,352.32
Disclosure

SEC source: 0001415889-25-003179 · form4-02062025_020220.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 784,239

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

Read SEC document
November 06, 2024 Filed Nov 8, 2024 21:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $0.86 $2,030.46
Disclosure

SEC source: 0001415889-24-026429 · form4-11082024_041104.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 787,487

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,751 $0.80 $2,200.80
Disclosure

SEC source: 0001415889-24-026126 · form4-11052024_041109.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 789,848

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
September 03, 2024 Filed Sep 4, 2024 20:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 12,657 $0.83 $10,505.31
Disclosure

SEC source: 0001415889-24-022768 · form4-09042024_040914.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 792,599

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
August 06, 2024 Filed Aug 8, 2024 20:30 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $0.87 $2,054.07
Disclosure

SEC source: 0001415889-24-020990 · form4-08082024_080840.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 805,256

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,751 $0.94 $2,585.94
Disclosure

SEC source: 0001415889-24-020739 · form4-08052024_040812.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 807,617

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
May 06, 2024 Filed May 7, 2024 20:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $1.75 $4,131.75
Disclosure

SEC source: 0001415889-24-012457 · form4-05072024_040501.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 810,368

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
May 01, 2024 Filed May 3, 2024 20:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,751 $1.77 $4,869.27
Disclosure

SEC source: 0001415889-24-012155 · form4-05032024_040507.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 812,729

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:15 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 12,657 $2.27 $28,731.39
Disclosure

SEC source: 0001415889-24-006592 · form4-03052024_040323.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 815,480

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
February 06, 2024 Filed Feb 8, 2024 22:08 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,788 $2.32 $6,468.16
Disclosure

SEC source: 0001415889-24-003038 · form4-02082024_100240.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 828,137

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
January 29, 2024 Filed Feb 1, 2024 00:35 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 470,000 $0.00 Strike: $2.41 $0.00
Disclosure

SEC source: 0001415889-24-002098 · form4-02012024_120236.xml · derivative · entry 2

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 470,000

Underlying: Common Stock · 470,000 shares

Expires 2034-01-28

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
January 29, 2024 Filed Feb 1, 2024 00:35 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantCommon Stock 150,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002098 · form4-02012024_120236.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 830,925

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.

Read SEC document
November 06, 2023 Filed Nov 8, 2023 21:13 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $1.82 $4,297.02
Disclosure

SEC source: 0001209191-23-054699 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 680,925

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 20:28 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 12,657 $2.67 $33,794.19
Disclosure

SEC source: 0001209191-23-048384 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 683,286

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 20:29 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $2.67 $6,303.87
Disclosure

SEC source: 0001209191-23-045177 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 695,943

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

Read SEC document
May 08, 2023 Filed May 10, 2023 20:19 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 2,361 $4.14 $9,774.54
Disclosure

SEC source: 0001209191-23-028473 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 698,304

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

Read SEC document
March 01, 2023 Filed Mar 2, 2023 23:39 UTC Vor Biopharma Inc. VOR · Entity 4763 Tax withholdingCommon Stock 12,657 $5.51 $69,740.07
Disclosure

SEC source: 0001209191-23-014923 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,665

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

Read SEC document
February 06, 2023 Filed Feb 8, 2023 21:28 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 257,500 $0.00 Strike: $5.55 $0.00
Disclosure

SEC source: 0001209191-23-007794 · doc4.xml · derivative · entry 2

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,500

Underlying: Common Stock · 257,500 shares

Expires 2033-02-05

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 06, 2023 Filed Feb 8, 2023 21:28 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantCommon Stock 128,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-007794 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 713,322

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date.

Read SEC document
September 13, 2022 Filed Sep 15, 2022 20:18 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 172,500 $0.00 Strike: $4.97 $0.00
Disclosure

SEC source: 0001209191-22-050071 · doc4.xml · derivative · entry 2

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,500

Underlying: Common Stock · 172,500 shares

Expires 2032-09-12

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

Read SEC document
September 13, 2022 Filed Sep 15, 2022 20:18 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantCommon Stock 172,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-050071 · doc4.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 584,572

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in four equal installments on each of March 1, 2023, September 1, 2023, March 1, 2024 and September 1, 2024, in each case, subject to the Reporting Person's continued service as of each such date.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:25 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 376,000 $0.00 Strike: $8.63 $0.00
Disclosure

SEC source: 0001209191-22-006790 · doc4.xml · derivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,000

Underlying: Common Stock · 376,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: This option vests over four years in equal monthly installments beginning on February 1, 2022.

Read SEC document
February 05, 2021 Filed Feb 9, 2021 22:10 UTC Vor Biopharma Inc. VOR · Entity 4763 GrantEmployee Stock Option (right to buy) · Derivative 51,060 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-21-008878 · doc4.xml · derivative · entry 1

ANG ROBERT · CIK 0001741283 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,060

Underlying: Common Stock · 51,060 shares

Expires 2031-02-04

F1 · derivative.exercise_date: 1/48th of the shares underlying the option vest in equal monthly installments commencing on February 19, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 18:18 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $6.13 $0.00
Disclosure

SEC source: 0001694187-19-000011 · wf-form4_155148228112386.xml · derivative · entry 2

ANG ROBERT · CIK 0001741283 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-02-26

F2 · derivative.exercise_date: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 18:18 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001694187-19-000011 · wf-form4_155148228112386.xml · nonDerivative · entry 1

ANG ROBERT · CIK 0001741283 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,525

F1 · shares: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.